NASDAQ: APGNApexigen Inc Stock
$0.55+0.01 (+1.85%)
Updated Jun 1, 2023
APGN Price
$0.55
Fair Value Price
$748.61
Market Cap
$13.56M
52 Week Low
$0.33
52 Week High
$31.35
P/E
-0.47x
P/B
4.36x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$29.08M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.65
Operating Cash Flow
-$29M
Beta
0.51
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
APGN Overview
Apexigen Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody therapeutics for oncology. It develops a pipeline of product candidates, including APX005M, a humanized agonist antibody that is in Phase II clinical development for the treatment of solid tumors, such as melanoma, esophageal and gastroesophageal junction, sarcoma, and rectal and ovarian cancers in combination with immunotherapy, chemotherapy, radiation therapy, and cancer vaccines; and APX601, a humanized antagonist antibody that is in Phase I/II clinical trial for the treatment of multiple tumor indications, as well as APX801, an NK cell engager to activate natural killer cells to killing of tumor cells. The company was founded in 2010 and is based in San Carlos, California.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how APGN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
APGN ($0.55) is undervalued by 99.93% relative to our estimate of its Fair Value price of $748.61 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
APGN ($0.55) is significantly undervalued by 99.93% relative to our estimate of its Fair Value price of $748.61 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
APGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more APGN due diligence checks available for Premium users.
Be the first to know about important APGN news, forecast changes, insider trades & much more!
APGN News
Valuation
APGN fair value
Fair Value of APGN stock based on Discounted Cash Flow (DCF)
Price
$0.55
Fair Value
$748.61
Undervalued by
99.93%
APGN ($0.55) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
APGN ($0.55) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
APGN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
APGN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.47x
Industry
11.46x
Market
52.37x
APGN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.36x
Industry
5.14x
APGN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
APGN's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.1M
Profit Margin
0%
APGN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$17.6M
Liabilities
$14.5M
Debt to equity
4.65
APGN's short-term assets ($16.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
APGN's short-term assets ($16.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
APGN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.8M
Investing
$2.2M
Financing
$2.5M
APGN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
APGN vs Biotech Stocks
Apexigen Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.